Clinical Trial Update: PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection [Phase 3]

View source ↗

Summary

A Phase 3 trial investigating palbociclib and circulating tumor DNA ESR1 mutation detection in metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ibrance (palbociclib) (palbociclib)

Snippet

Sponsor: UNICANCER | Conditions: Metastatic Breast Cancer | Phase 3 | Status: COMPLETED